[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.159.27. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Special Communication
November 2015

Treatment of Retinoblastoma in 2015Agreement and Disagreement

Author Affiliations
  • 1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Department of Ophthalmology, Weill-Cornell Medical Center, New York, New York
  • 3Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
  • 4Jules-Gonin Eye Hospital, Faculté de Biologie et Médecine de Lausanne, Lausanne, Switzerland
  • 5Research Institute, Hospital J.P. Garrahan, Buenos Aires, Argentina
JAMA Ophthalmol. 2015;133(11):1341-1347. doi:10.1001/jamaophthalmol.2015.3108
Abstract

The management of intraocular retinoblastoma is rapidly changing, and even recent reviews on the subject are behind existing practices. The 4 authors of this report collectively represent their management strategies with an emphasis on areas of agreement and disagreement. Ophthalmic artery chemosurgery and intravitreous chemotherapy have completely replaced external beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90% without evidence of compromising patient survival.

×